Vector Labs Ab03058-10.29-BS Anti-VEGFR2 [IMC-1121B (Ramucirumab)], Human Fab fragment, His-Tagged, kappa (1 mg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: IMC-1121B (Ramucirumab)
Heavy Chain Modification: His-Tagged
Synonyms: Vascular endothelial growth factor receptor 2; kinase insert domain-containing receptor; KDR; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; CD309; VEGFR-2; Cyramza; LY3009806; 947687-13-0
Amount: 1 mg
Application Codes Clone: FC; IHC; crystallography; in vitro; in vivo; therapeutic
Shipping Temperature: Wet Ice
Buffer Composition: PBS only.
Original Format: Fab
Storage Temperature: Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This reformatted human antibody was made using the variable domain sequences of the original Human Fab format for improved compatibility with existing reagents assays and techniques.
Specificity Statement: The antibody specifically recognizes VEGFR-2 and it binds to domain 3 of VEGFR2. VEGFR2 is a tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. It plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells.
Application Notes: The antibody blocked the VEGFR2/VEGF interaction with an IC50 value of 1 nM and 0.8 nM for Fab and IgG1 fragments respectively. The binding affinity of the Fab and IgG fragments to VEGFR-2 was measured by surface plasmon resonance (Kd= 100 pM and 50 pM respectively). The IgG1 fragment was able to inhibit VEGF-stimulated VEGFR2 phosphorylation in endothelial cells. The epitope mapping of this antibody demonstrated the antibody interacted with the third immunoglobulin domain within the extracellular region of VEGFR2 (Lu et al, 2003; pmid:12917408). The antibody (IgG1) strongly inhibited VEGF-induced migration of human leukemia cells in vitro, and when administered in vivo, significantly prolonged survival of NOD-SCID mice inoculated with human leukemia cells. (Zhu et al, 2003; pmid:12646950). The Fab fragment was able to strongly block VEGFR2/VEGF interaction, resulting in potent inhibition of an array of biological activities of VEGF, including activation of the receptor and its signaling pathway, intracellular calcium mobilization, and migration and proliferation of endothelial cells. (Miao et al., 2006; pmid:16682007). The antibody has demonstrated some antitumor efficacy in humans, including a decrease in tumor vascularity (Spratlin et al, 2010; pmid:21222245). The structure of the Fab fragment alone and in complex with domain 3 of VEGFR2 was determined (Franklin et al, 2011; pmid:21827946).

Product Class:	Purified
Clone ID:	IMC-1121B (Ramucirumab)
Heavy Chain Modification:	His-Tagged
Synonyms:	Vascular endothelial growth factor receptor 2; kinase insert domain-containing receptor; KDR; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; CD309; VEGFR-2; Cyramza; LY3009806; 947687-13-0
Amount:	1 mg
Application Codes Clone:	FC; IHC; crystallography; in vitro; in vivo; therapeutic
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS only.
Original Format:	Fab
Storage Temperature:	Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This reformatted human antibody was made using the variable domain sequences of the original Human Fab format for improved compatibility with existing reagents assays and techniques.
Specificity Statement:	The antibody specifically recognizes VEGFR-2 and it binds to domain 3 of VEGFR2. VEGFR2 is a tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. It plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells.
Application Notes:	The antibody blocked the VEGFR2/VEGF interaction with an IC50 value of 1 nM and 0.8 nM for Fab and IgG1 fragments respectively. The binding affinity of the Fab and IgG fragments to VEGFR-2 was measured by surface plasmon resonance (Kd= 100 pM and 50 pM respectively). The IgG1 fragment was able to inhibit VEGF-stimulated VEGFR2 phosphorylation in endothelial cells. The epitope mapping of this antibody demonstrated the antibody interacted with the third immunoglobulin domain within the extracellular region of VEGFR2 (Lu et al, 2003; pmid:12917408). The antibody (IgG1) strongly inhibited VEGF-induced migration of human leukemia cells in vitro, and when administered in vivo, significantly prolonged survival of NOD-SCID mice inoculated with human leukemia cells. (Zhu et al, 2003; pmid:12646950). The Fab fragment was able to strongly block VEGFR2/VEGF interaction, resulting in potent inhibition of an array of biological activities of VEGF, including activation of the receptor and its signaling pathway, intracellular calcium mobilization, and migration and proliferation of endothelial cells. (Miao et al., 2006; pmid:16682007). The antibody has demonstrated some antitumor efficacy in humans, including a decrease in tumor vascularity (Spratlin et al, 2010; pmid:21222245). The structure of the Fab fragment alone and in complex with domain 3 of VEGFR2 was determined (Franklin et al, 2011; pmid:21827946).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews